SELLAS Life Sciences Group, Inc. quarterly report, Q2 FY2026

Business Context and Reporting Period

Company: SELLAS Life Sciences Group, Inc. (SLS)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2026
Business Overview: A late-stage clinical biopharmaceutical company focused on novel cancer therapeutics. Lead candidates include galinpepimut-S (GPS), a WT1-targeting immunotherapy, and SLS009 (tambiciclib), a CDK9 inhibitor. The company operates as a single segment and has no product sales revenue.

Key Financial Metrics

Metric (in thousands) Six Months Ended June 30, 2026 Six Months Ended June 30, 2025
Revenue $0 $0
Net Loss $(18,012) $(12,414)
Net Loss Per Share (Basic & Diluted) $(0.10) $(0.13)
Operating Expenses $19,881 $12,936
Interest Income $1,869 $522
Cash and Cash Equivalents (End of Period) $138,343 $25,397
Net Cash Used in Operating Activities $(16,434) $(16,400)
Net Cash Provided by Financing Activities $82,984 $27,811
Accumulated Deficit $(293,000) $(260,539)

Material Changes vs. Prior Period

  • Capital Raise: The company received approximately $82.9 million from the exercise of 48.8 million warrants at a weighted average price of $1.70 per share during the six months ended June 30, 2026. This significantly increased cash balances from $71.8 million to $138.3 million.
  • Operating Expenses: Total operating expenses increased by $6.9 million (54%) compared to the prior year period.
    • R&D Expenses: Increased by $4.3 million, driven by a $2.3 million rise in manufacturing costs for GPS (preparing for potential BLA filing) and increased clinical trial costs for SLS009.
    • G&A Expenses: Increased by $2.6 million, primarily due to a one-time $1.0 million charge for legal fees and arbitration costs related to the 3D Medicines dispute.
  • Interest Income: Increased by $1.3 million due to higher cash balances and interest rates.
  • Share Count: Weighted average shares outstanding increased significantly due to warrant exercises, diluting the per-share loss despite a higher absolute net loss.

Guidance, Outlook, and Risks

  • Liquidity Outlook: Management expects current cash of $138.3 million to fund operations for at least the next 12 months. The company has a $150 million at-the-market (ATM) sales agreement with TD Cowen but has not sold shares under it yet.
  • Clinical Progress:
    • GPS: The Phase 3 REGAL study in AML has reached 78 of 80 required events for final analysis. The company is preparing for a potential Biologics License Application (BLA).
    • SLS009: Phase 2 trial in relapsed/refractory AML met primary endpoints. A new randomized Phase 2 trial in newly diagnosed, first-line AML began enrollment in Q1 2026. A European study via the IMPACT-AML network is also underway.
  • Legal Contingency: The company lost an arbitration against 3D Medicines regarding milestone payments. Claims were dismissed, and the company was ordered to pay approximately $1.0 million in legal and administrative fees, recognized in Q2 2026. $191.5 million in potential future milestones under the 3D Medicines agreement remain unearned.
  • Risks: Continued operating losses, dependence on successful clinical outcomes, need for future capital raises, and regulatory uncertainties.

Investor Verification Checklist

  • Cash Runway: Verify the $138.3 million cash balance and the 12-month operational runway estimate against current burn rates.
  • GPS Trial Status: Monitor the timing of the 80th event in the REGAL study and the subsequent final analysis results.
  • SLS009 Enrollment: Track enrollment progress in the new first-line AML Phase 2 trial and the European IMPACT-AML study.
  • Legal Exposure: Confirm the payment of the $1.0 million arbitration cost and assess any remaining risks regarding the 3D Medicines agreement.
  • Dilution: Review the impact of the recent warrant exercises on share count and the potential dilution from the unused $150 million ATM facility.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.